FY2025 · ended Dec 31, 2025 · Revenue $73,066, -90.9% YoY · Filed Apr 15, 2026
Endovia Health Sciences, Inc. (EDVA) files with the SEC under industry code 2080, Beverages. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $73,066 and a net loss of $25.2 million. As of Jun 30, 2026 it held $242,702 in cash and investments and $57,114 in total debt.
Revenue (TTM)
$32,090
+101.8% vs year-ago TTM
Net income (TTM)
$-17.28M
+33.3% vs year-ago TTM
Operating cash flow (TTM)
$-5.48M
-11.3% vs year-ago TTM
Free cash flow
$-7.31M
+28.4% vs prior year
EPS (TTM)
$-5.74
+78.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
10.86M
+9.1% vs prior year
Net cash
$185,588
as of Jun 30, 2026
Operating margin
-43665.5%
FY 2026
Company profile
- Industry
- Beverages (SIC 2080)
- Listed as
- EDVA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Fort Lauderdale, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1553788
- Former names
- SPLASH BEVERAGE GROUP, INC. (until Aug 21, 2026); Canfield Medical Supply, Inc. (until Aug 5, 2020)
Other Beverages companies
- Coca Cola Co KO
- Pepsico Inc PEP
- Diageo PLC DEO
- Keurig Dr Pepper Inc. KDP
- Ambev S.A. ABEV
- Constellation Brands, Inc. STZ
- Brown Forman Corp BF-B
- Primo Brands Corp PRMB
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $73,066 | $801,273 | $18.9M | $18.1M | $11.3M |
| Operating income | -$14.2M | -$9.9M | -$15.3M | -$21.4M | -$29.1M |
| Net income | -$25.2M | -$23.8M | -$21.0M | -$21.7M | — |
| Diluted EPS | -$11.97 | — | — | — | -$1.02 |
| Operating cash flow | -$4.8M | -$7.3M | -$10.2M | -$14.0M | -$14.7M |
| Free cash flow | — | -$7.3M | -$10.2M | -$14.1M | — |
| Total assets | $965,694 | $2.8M | $9.9M | $17.3M | $16.4M |
| Total liabilities | $16.3M | $21.4M | $15.5M | $8.0M | $7.5M |
| Stockholders' equity | -$15.3M | -$18.6M | -$5.6M | $9.3M | $8.9M |
| Cash and investments | $281,435 | $13,789 | $379,978 | $4.4M | $4.2M |
| Total debt | $57,114 | $2.3M | $1.0M | $3.3M | $1.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Oct 27, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Oct 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 24, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 22, 2026 |
All 434 Endovia Health Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.